Rankings
▼
Calendar
IMUX FY 2019 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena
IMUX
Immunic, Inc.
$138M
FY 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$50,000
Operating Income
-$37M
Net Income
-$35M
EPS (Diluted)
$-4.51
Cash Flow
Operating Cash Flow
-$29M
Free Cash Flow
-$29M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$66M
Total Liabilities
$8M
Stockholders' Equity
$58M
Cash & Equivalents
$29M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$50,000
-$15,000
-233.3%
Operating Income
-$37M
-$42M
+11.9%
Net Income
-$35M
-$41M
+16.0%
← Q4 2018
All Quarters
Q1 2019 →